Welcome to our dedicated page for Burcon Nutrascience news (Ticker: BRCNF), a resource for investors and traders seeking the latest updates and insights on Burcon Nutrascience stock.
Burcon NutraScience Corporation reports developments tied to plant-based protein ingredients for the food and beverage industry. Company updates cover commercialization of high-performance protein products such as Peazzaz®, FavaPro and Puratein®, production scale-up, customer adoption across beverage, nutrition and plant-based food applications, and work with manufacturing partners to support demand.
Recurring news also includes operating and financial results, convertible-debenture financing, shareholder voting matters, warrant amendments, board changes and other governance actions. Burcon's communications frequently reference its patent portfolio for proteins derived from pea, canola, soy, hemp, sunflower and other plant sources.
Burcon (OTCQB: BRCNF) appointed Chris Bunio to its board effective April 29, 2026, and announced departures of directors Jeanne McCaherty and Richard Nazur Jr..
Bunio brings nearly 30 years in technology, founded and operationalized TheoryMesh in 2021, and previously spent 18 years at Microsoft in global senior roles. McCaherty joined Burcon in July 2021; Nazur joined in September 2025.
Burcon (OTCQB: BRCNF) closed the final tranche of a non‑brokered private placement of convertible debentures for an aggregate principal amount of $6.9 million on April 27, 2026. The final tranche raised $2.9 million, with insiders subscribing about $4.4 million in aggregate.
The Company received approximately $2.35 million cash from the final tranche after offsetting $546,678 payable to an entity related to an insider. Proceeds will fund inventory, labor, production capability, infrastructure planning, loan repayments and general corporate purposes.
Burcon (OTCQB: BRCNF) reported operational and commercial progress on April 20, 2026. The company achieved record production, raising average daily output by approximately 40% versus the calendar Q1 average, and expanded to more than 20 buying customers across multiple food and beverage categories. Burcon and manufacturing partner RE ProMan are evaluating additional capacity expansion to meet rising demand across products such as Peazzaz, FavaPro and Puratein.
Management said the milestones support scaling toward 2026 goals while focusing on efficient growth and customer onboarding.
Burcon (OTCQB:BRCNF) closed the second tranche of a non-brokered private placement of convertible debentures for $2.75 million on February 27, 2026, bringing cash raised to $4.0 million to date.
The Private Placement totals up to $6.9 million and the Company expects to close a final tranche (a $2.90 million non-cash loan conversion) prior to April 24, 2026. Insiders have subscribed for $2.7 million in principal so far and the Company will rely on MI 61-101 exemptions for related-party participation.
Burcon (OTCQB: BRCNF) announced that all matters at its 2026 special meeting of shareholders held February 20, 2026 were duly approved. Shareholders approved the Convertible Debenture Financing and an amendment to the expiry date of insider-held warrants.
Disinterested shareholder approval was obtained where required. The company filed detailed voting results on SEDAR+ and expects to close the Convertible Debenture Financing on or about February 24, 2026, according to the company.
Burcon (OTCQB: BRCNF, TSX: BU) reported fiscal Q3 results for the period ended December 31, 2025, with revenue of $739,000 (up ~1100% year-over-year) and nine-month revenue of $1.439 million (up ~325% YoY). Burcon closed a $1.25 million tranche of a $6.9 million private placement and drew a related-party $480,000 loan to bridge funding while scaling production at Galesburg.
Net loss for nine months was $10.7 million and cash was $1.3 million at quarter end; the company expects the final private placement tranche to close on or about February 24, 2026.
Burcon (OTCQB: BRCNF) will hold a special shareholders meeting on February 20, 2026 (virtual) to seek disinterested shareholder approval to amend certain insider warrants. The company is extending the expiry of outstanding warrants totaling 1,544,249 common shares to June 30, 2027.
The Board has already amended Non-insider Warrants (effective February 19, 2026). Amendments for insider-held warrants are subject to disinterested shareholder approval at the Meeting. Management says exercising warrants could provide cash to accelerate capacity expansion.
Burcon (OTCQB: BRCNF) will host an investor conference call and webcast on Wednesday, February 11, 2026 at 5:00 p.m. ET to discuss fiscal 2026 third quarter results for the period ended December 31, 2025.
A press release with the Company's financial results will be issued prior to the call; a webcast link and archived replay will be available on Burcon's website under Presentations.
Burcon (OTCQB: BRCNF, TSX: BU) said it increased its non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million on January 9, 2026, citing strong investor demand. Insiders and manufacturing partner owners have committed a minimum of $5.0 million. The TSX granted conditional approval pending compliance, including receipt of disinterested shareholder approval. Management reaffirmed a revenue target of more than $10 million for calendar 2026.
Burcon (OTCQB: BRCNF) closed the first tranche of a non‑brokered private placement of convertible debentures for $1.25 million, part of an aggregate financing of up to $6.3 million. Insiders and manufacturing partner owners committed at least $5.0 million in principal. The financing is conditionally approved by the TSX and the final tranche requires disinterested shareholder approval expected after a special meeting on February 20, 2026. Each debenture carries 15% interest, 48‑month maturity, and is convertible at $1.60 per share (with pre‑funded warrant option). Proceeds will fund production scale‑up, infrastructure planning, general corporate purposes and repay a short‑term loan.